肝癌介入治疗新药米铂的药理与临床研究  

Progress in pharmacological and clinical studies of miriplatin on interventional therapy of hepatocellular carcinoma

作　　者：赵俊[1] 马俊杰[1] 

机构地区：[1]江苏奥赛康药业股份有限公司,南京211112

出　　处：《中国新药杂志》2012年第18期2097-2099,共3页Chinese Journal of New Drugs

摘　　要：米铂是第三代铂类抗肿瘤药物,其与碘化油亲和性高,且肝动脉内给药后滞留于肿瘤部位,混悬液中的铂成分可长时间缓慢释放进入血液或组织中。其与DNA结合,通过阻止DNA合成而产生细胞毒效应。临床研究结果表明,米铂治疗肝细胞癌具有良好的疗效和安全性。现对其药理学、药动学、临床研究及安全性评价等作一综述。Miriplatin is a thirdgeneration platinum compound developed to treat hepatocellular carcinoma （HCC）. It is administered via the hepatic artery using the carrier lipiodol that consists of ethyl esters of iodized poppy seed oil. Miriplatin has a high affinity for lipiodol and it is anticipated to exert antitumor effects with pro longed retention along with local lipiodol at the tumor site. Therefore, it is suggested that the active compound re leased from miriplatin/lipiodol can bind to DNA and produce a cytotoxic effect. The clinical research shows that miriplatin has beneficial curative effect and safety in the treatment of hepatocellular carcinoma. This article will summarize its pharmacology, pharmacokinetics, clinical research, and safety evaluation.

关 键 词：米铂 肝癌 药理作用 临床研究 

分 类 号：R979.1[医药卫生—药品]